NEW YORK--(BUSINESS WIRE)--May 23, 2006--Daxor Corporation, (AMEX: DXR - News): Daxor Corporation, (AMEX: DXR - News), a medical instrumentation and biotechnology company, today announced first quarter earnings for 2006. For the three months ended March 31, 2006 total revenues increased by 51.3% to $ 1,680,424 from $ 1,110,699 for the corresponding period in 2005. Operating revenues increased by 13.9% to $ 342,146 in 2006 from $ 300,356 for 2005. Total Operating Expenses increased by 4.49% in 2006 to $1,614,265 vs. $ 1,538,413 in 2005. This was mostly a result of increased marketing efforts and research and development expenses. In Q1 2006 six contracts were signed for instruments on a trial basis. Blood volume kit sales have risen 26% as compared to 2005. The Company is expanding research and marketing staff. The Company continues to be dependent on investment income to defray its operating losses.
